Essex Bio-Technology Limited (SEHK: 1061)
Health Care · Biotechnology · CN
HK$2.08
-3.26% today · -55.3% 1Y
Essex Bio-Technology Limited (SEHK: 1061) operates in the Biotechnology industry within the Health Care sector. The company is valued at $149.73M and employs 1,240 people.
Over the last twelve months the share price has lost 55.3%, trading between 2.01 and 4.88.
Tweenvest scores Essex Bio-Technology Limited across four factors: quality 80/100, value 87/100, growth 53/100, dividend 93/100. Its strongest factor is dividend.
1061 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $149.73M
- Revenue (TTM)
- $219.58M
- P/E
- 4.44
- EPS
- 0.47
- Dividend yield
- 6.51%
- Beta (5Y)
- -0.01
- 52-week high
- HK$4.88
- 52-week low
- HK$2.01
- Avg volume (3M)
- —
- Shares outstanding
- 564.91M
- Employees
- 1,240
- Next earnings
- —
About Essex Bio-Technology Limited
Essex Bio-Technology Limited operates as an investment holding company, specializing in the development, manufacturing, distribution, and sale of biopharmaceutical products. Its business activities extend across the People's Republic of China and into international territories. The company organizes its operations into two primary segments: Ophthalmic Products and Surgical Products. A significant focus of its research and development is on basic fibroblast growth factor (bFGF) products, which are utilized to promote cellular proliferation, differentiation, and migration. Its ophthalmic offerings include the Beifushu series, comprising eye drops, eye gel, and unit-dose eye drops. Other eye care solutions feature Tobramycin eye drops, Levofloxacin eye drops, Sodium Hyaluronate eye drops, and Iodized Lecithin Capsules. For surgical and wound care needs, the company supplies Beifuji sprays and lyophilized powder, along with Beifuxin gels. These are applied in cases of burns, scalds, acute wounds, surgical incisions, chronic wounds, and skin grafting, among other uses. In addition to its proprietary innovations, Essex Bio-Technology distributes ophthalmic and surgical products sourced from third-party manufacturers. Its diverse product portfolio also encompasses Carisolv dental caries removal gel and Yi Xue An Granules. The company holds licensing agreements with both Mitotech S.A. and Mitotech LLC. Founded in 1990, Essex Bio-Technology Limited maintains its headquarters in Zhuhai, China.
- ISIN
- KYG312371035
- Founded
- 1990
- Listed since
- Jun 27, 2001
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Tiziana Life Sciences LtdNasdaqCM: TLSA | $153.88M | $1.09 | -8.40% |
| NovaBridge BiosciencesNasdaqGM: NBP | $153.12M | $1.32 | -5.38% |
| BioInvent International AB (publ)OM: BINV | $152.68M | Skr23.10 | -0.43% |
| Minerva Neurosciences, Inc.NasdaqCM: NERV | $151.84M | $2.89 | -9.12% |
| Scancell Holdings plcAIM: SCLP | $149.18M | £0.09 | +0.54% |
| Molecular Partners AGSWX: MOLN | $148.00M | CHF3.21 | -3.60% |
| Actinogen Medical LimitedASX: ACW | $147.68M | AU$0.06 | +1.85% |
| JW (Cayman) Therapeutics Co. LtdSEHK: 2126 | $146.12M | HK$2.83 | +5.21% |
Figures last refreshed Oct 11, 2026.